Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation.
Mantle Cell Lymphoma
DRUG: Temsirolimus|DRUG: Bendamustine|DRUG: Temsirolimus
Phase I: Dose-finding, Is the combination of temsirolimus alongside with bendamustine at the suggested dose feasible or are dose reductions necessary. Number of dose reductions or delays of therapy due to hematologic toxicities (CTCAE) or other adverse events according to protocoll., 6 months|Phase II: Response Rate (Overall response rate, complete and partial response), What is the response rate of a therapy with temsirolimus and bendamustine., 6 months
Progression free survival, This is defined as the period of time between the admission into the clinical trial and the progression of the lymphoma or death of any kind., 2 years|Safety and Tolerability of Temsirolimus and Bendamustine Combination Therapy, Detection of overall toxicity, serious adverse events (SAE), suspected unexpected serious adverse reactions (SUSAR) during treatment with temsirolimus and bendamustine., 2 years
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation.